[FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Cardiovascular disease prevention necessitates aggressive LDL cholesterol reduction.
• The "lower is better" principle guides lipid-lowering therapy.
• Combined therapies enhance LDL cholesterol lowering.

Purpose of the Study:

• To introduce Atozet®, a novel fixed-dose combination of atorvastatin and ezetimibe.
• To highlight the synergistic LDL-lowering effects of combining a statin with an intestinal cholesterol absorption inhibitor.

Main Methods:

• Review of pharmacological principles of combined lipid-lowering therapy.
• Introduction of a new fixed-dose combination product.

Main Results:

• Atorvastatin is more potent than simvastatin.
• The fixed combination of atorvastatin and ezetimibe (Atozet®) is expected to provide superior LDL cholesterol reduction.
• This combination facilitates achieving therapeutic goals in high-risk patients.

Conclusions:

• Atozet® offers a potent therapeutic option for managing severe hypercholesterolemia.
• The combination targets both cholesterol synthesis and absorption for maximum LDL reduction.
• This novel therapy aids in achieving cardiovascular prevention goals for high-risk individuals.